More than 300 patients and members learned about our latest achievements and groundbreaking research at the Moorfields Annual General Meeting (AGM) on Tuesday 25 July.
The event was an opportunity for us to share some of the exciting new initiatives that we are working on and discuss progress we have made over the past 12 months in delivering our key objectives. Some of the big topics from the meeting were the launch of our new five year strategy, the two major funding awards for our National Institute of Health Research (NIHR) Biomedical Research Centre and Clinical Research Facility and the trust achieving an overall ‘Good’ rating from the Care Quality Commission (CQC).
Tessa Green, chairman, opened the meeting by commending the annual report and accounts for the year 2016/17 and Rob Jones, vice chairman of the membership council, explained the important role of Moorfields’ governors in representing the local communities they serve.
Reflecting on his first year at Moorfields, David Probert, chief executive, thanked staff for making it “such a success” after seeing more patients than ever before. Looking ahead, David shared our goals and aspirations for the next five years which are encompassed in our new strategy, a vision of excellence. Watch David’s presentation below.
Two leading experts from Moorfields and the UCL Institute of Ophthalmology presented on the latest research that is being carried out to develop new treatments for patients with glaucoma and inherited eye disease.
Professor Sir Peng Tee Khaw, director of research and development, presented on the latest advances in the management of glaucoma and how research from the NIHR Biomedical Research Centre at Moorfields and UCL is creating new life changing treatments for people with sight loss around the world. Professor Khaw’s presentation will be available to watch online soon.
Dr Mariya Moosajee, consultant ophthalmologist, spoke about significant advances that have been made in improving our understanding of inherited eye disease and how our genetic code determines how our eyes develop. Using gene editing technology, Mariya hopes to develop the first targeted therapy to treat inherited eye disease, which is the leading cause of blindness in children. Watch Mariya's presentation below.
Notes to editors
For media enquires, please contact George Allen, Moorfields Eye Hospital press office. Email: email@example.com.
Was this information useful? Please rate the page.